Early findings on immune escape and transmissibility, combined with danger posed by Delta, heighten urgency of vaccination, testing, other safety measures.

Can the current crop of vaccines get us to herd immunity even if variants become widespread? A Harvard immunologist says yes.

Vaccines that might protect against COVID-19 have entered phase 3 trials — the last step before regular approval in humans — in record time, but the virus has moved faster, experts say.